Search Results - "Taskinen, M-R"

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors: Keech, A. Simes, R. J. Barter, P. et al.

Source: Lancet. 11/26/2005, Vol. 366 Issue 9500, p1849-1861. 13p.

Subjects: Diabetes complications, Patients, Coronary disease, Type 2 diabetes, Myocardial infarction, Cardiovascular diseases, Clinical trials, Medical research

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.

Authors: Taskinen, M.‐R. Söderlund, S. Bogl, L. H. et al.

Source: Journal of Internal Medicine. Aug2017, Vol. 282 Issue 2, p187-201. 15p. 3 Charts, 5 Graphs.

Ectopic lipid storage and insulin resistance: a harmful relationship.

Authors: Borén, J. Taskinen, M.‐R. Olofsson, S.‐O. et al.

Source: Journal of Internal Medicine. Jul2013, Vol. 274 Issue 1, p25-40. 16p. 3 Diagrams.

Kinetic studies to investigate lipoprotein metabolism.

Authors: Borén, J. Taskinen, M.-R. Adiels, M.

Source: Journal of Internal Medicine. Feb2012, Vol. 271 Issue 2, p166-173. 8p. 4 Diagrams, 1 Graph.

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Authors: Taskinen, M.-R. Rosenstock, J. Tamminen, I. et al.

Source: Diabetes, Obesity & Metabolism. Jan2011, Vol. 13 Issue 1, p65-74. 10p. 1 Diagram, 3 Charts, 5 Graphs.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors: Keech, A.C. Mitchell, P. Summanen, P.A. et al.

Source: Lancet. 11/17/2007, Vol. 370 Issue 9600, p1687-1697. 11p. 1 Diagram, 5 Charts, 6 Graphs.

Subjects: Clinical trial registries, Diabetic retinopathy treatment, Fenofibrate, Treatment of eye diseases, Retinal diseases, Diabetes complications, Laser surgery, Antilipemic agents, Blood pressure, Blood sugar, Blood lipids, Health outcome assessment

Authors' reply.

Authors: Keech, A. Simes, R. J. Barter, P. et al.

Source: Lancet. 4/8/2006, Vol. 367 Issue 9517, p1142-1143. 2p.

Subjects: Letters to the editor, Clinical trials

A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.

Authors: Verrijken, A. Beckers, S. Francque, S. et al.

Source: Obesity (19307381). Oct2013, Vol. 21 Issue 10, p2138-2145.

Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins.

Authors: Kaye, S.M. Maranghi, M. Bogl, L.H. et al.

Source: Obesity (19307381). Sep2013, Vol. 21 Issue 9, p1815-1822.

This result is not displayed to guests.
Login for full access.

Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.

Authors: Björnson, E. Packard, C.J. Adiels, M. et al.

Source: Journal of Internal Medicine. Oct2020, Vol. 288 Issue 4, p422-438. 17p.

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes.

Authors: Matikainen, N. Taskinen, M.‐R.

Source: Diabetic Medicine. Jun2013, Vol. 30 Issue 6, p756-757. 2p. 1 Graph.

3WS20-6 Is liver the culprit of diabetic dyslipidemia?

Authors: Taskinen, M.-R.

Source: Atherosclerosis (Supplements). Jul2003, Vol. 4 Issue 2, p190. 2p.

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Authors: Björnson, E. Packard, C. J. Adiels, M. et al.

Source: Journal of Internal Medicine. May2019, Vol. 285 Issue 5, p562-577. 16p. 1 Diagram, 2 Charts, 3 Graphs.

52 DUAL METABOLIC DEFECTS ARE REQUIRED TO PRODUCE HYPERTRIGLYCERIDEMIA IN OBESE SUBJECTS

Authors: Adiels, M. Taskinen, M.-R. Westerbacka, J. et al.

Source: Atherosclerosis (Supplements). Jun2011, Vol. 12 Issue 1, p13-13. 1p.

Abstract: 69 IS HEPATIC STEATOTIS THE CULPRIT OF DYSLIPIDEMIA IN SUBJECTS WITH ABDOMINAL OBESITY?

Authors: Taskinen, M-R Adiels, M Söderlund, S et al.

Source: Atherosclerosis (Supplements). Jun2009, Vol. 10 Issue 2, pe30-e30. 1p.

1SOA03-4 DAIS: New results and links between correcting lipid abnormalities and cardiovascular benefits

Authors: Taskinen, M.-R. Vakkilainen, J. Ansquer, J.-C. et al.

Source: Atherosclerosis (Supplements). Jul2003, Vol. 4 Issue 2, p10. 1p.

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate - Authors' response.

Authors: Björnson, E. Packard, C.J. Taskinen, M.‐R. et al.

Source: Journal of Internal Medicine. Jan2020, Vol. 287 Issue 1, p118-118. 1p.